Processing

Please wait...

Settings

Settings

1. WO2013169546 - PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS

Publication Number WO/2013/169546
Publication Date 14.11.2013
International Application No. PCT/US2013/039164
International Filing Date 02.05.2013
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
415
1,2-Diazoles
4155
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
438
the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
C07D 471/10 (2006.01)
C07D 487/10 (2006.01)
A61K 31/4155 (2006.01)
A61K 31/438 (2006.01)
A61P 3/10 (2006.01)
CPC
A61K 2300/00
A61K 31/706
A61K 45/06
C07D 471/10
C07D 487/10
C07H 1/00
Applicants
  • ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285, US
Inventors
  • QU, Fucheng; US
  • MANTLO, Nathan Bryan; US
Agents
  • LENTZ, Nelsen L.; Eli Lilly and Company P. O. Box 6288 Indianapolis, Indiana 46206-6288, US
Priority Data
61/645,10110.05.2012US
61/769,22126.02.2013US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS
(FR) COMPOSÉS DE PYRAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE SGLT1
Abstract
(EN)
The present invention provides a compound of Formula (II): wherein X represents the following: or a pharmaceutically acceptable salt thereof.
(FR)
La présente invention concerne un composé de Formule (II) : X représentant ce qui suit : ou un sel pharmaceutiquement acceptable de celui-ci.
Latest bibliographic data on file with the International Bureau